市場調查報告書
商品編碼
603202

全球非何杰金氏淋巴瘤治療藥市場:成長,趨勢及預測(2017年∼2022年)

Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

國立癌症研究所報告,2016年非何杰金氏淋巴瘤的新罹患數為7萬2580件,在非何杰金氏淋巴瘤起因的死亡案例是2萬150件。市場有強力的開發平台,不過,由於Rituximab的化療主導目前的市場,後期階段所使用的NHL治療藥暢銷流行。預計非何杰金氏淋巴瘤的治療所使用的Rituximab的銷售量拉抬這個市場成長。

本報告提供全球非何杰金氏淋巴瘤治療市場相關調查,市場概要,各治療類型、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會、課題分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 市場定義
  • 粒度分級單位
  • 基本貨幣
  • 期間的重新評估與預測
  • 一般調查的前提條件
  • 報告的說明

第2章 調查方法

  • 簡介
  • 分析方法論
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論指南
    • 市場工程&計量經濟學模式

第3章 摘要整理

第4章 主要推論

第5章 市場概要及產業趨勢

  • 目前市場方案
  • 市場概況
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 難治性/復發性疾病治療的未滿足需求
    • 有前途的開發平台
  • 市場阻礙因素
    • Rituximab反抗性非何杰金氏淋巴瘤的增加
    • 嚴格的法規指南
  • 市場機會
  • 主要課題

第7章 全球非何杰金氏淋巴瘤治療藥:市場區隔

  • 治療各類型
    • 化療
    • 免疫療法
    • 標靶治療
    • 放射線治療
    • 幹細胞移植

第8章 全球非何杰金氏淋巴瘤治療藥市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(GCC)
    • 南非
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • Roche
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • Celgene
  • Millennium/Johnson-Johnson
  • Merck
  • Pharmacyclics/Janssen Biotech
  • Kyowa Hakko Kirin
  • CTI BioPharma
  • 其他

第11章 分析師對投資機會的見解

第12章 市場未來展望

目錄
Product Code: 46182

Certain factors that are driving the market growth include a rise in the prevalence of NHL, demand for innovative drugs and novel technologies, and an increase in the number of FDA approvals for NHL therapy drugs.

Key Highlights

  • In addition, an increase in public awareness about NHL, robust drug pipeline for the treatment of the disease, improved diagnostic techniques to detect NHL, and an increase in the prevalence of non-Hodgkin lymphoma are the factors fuelling the NHL therapeutics market across the world.
  • However, the high cost of NHL drugs and various complications associated with them are acting as major restraints for the non-Hodgkin lymphoma therapeutics market. Additionally, stringent regulatory guidelines are limiting the growth of the market.

Key Market Trends

The Radiation Therapy Segment is Expected to Hold a Significant Market Share over the Forecast Period

Radiotherapy is the use of high-energy beams or particles to kill cancer cells, and it can be delivered from a source outside the body, i.e., external beam radiation or internally, such as brachytherapy. Usually, radiation treatments are given five days per week for several weeks. Radiation therapy is most effective when this kind of lymphoma is only found in one part of the body. According to the American Cancer Society, non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States that accounts for about 4% of all cancers. For non-Hodgkin disease, radiation therapy is used in the early stages. In the case of advanced lymphomas, radiation therapy is used along with chemotherapy for better treatment of NHL. If the lymphoma is widespread, palliative radiotherapy is very helpful. Radiotherapy is often very good at destroying non-Hodgkin disease cells. It mainly helps in relieving the symptoms caused by the lymphomas.

Asia-Pacific is Expected to Show the Highest Growth Rate over the Forecast Period

By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. North America dominates the non-Hodgkin lymphoma therapeutics market, due to increasing technological advancements and the rising incidences of NHL in the country. However, Asia-Pacific is expected to propel the non-Hodgkin lymphoma therapeutics market, owing to factors, such as increasing accessibility to healthcare facilities in the region and increasing prevalence of NHL. According to the research article published in 2018, it was estimated that the incidence rate of non-Hodgkin lymphoma was 7.11 per 100,000 per year in China. As the incidence and prevalence of non-Hodgkin lymphoma are increasing Y-o-Y, many manufacturing companies are investing to develop novel drug therapies to meet the growing demand for therapeutics. Hence, with the growing awareness of the disease, increasing government initiatives, and an increase in the burden of disease, the market is expected to grow over the forecast period.

Competitive Landscape

The non-Hodgkin lymphoma therapeutics market is highly competitive and consists of a few major players. Companies, like AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, hold substantial market shares in the non-Hodgkin lymphoma therapeutics market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Non-Hodgkin Lymphoma (NHL)
    • 4.2.2 Demand for Innovative Drugs and Novel Technologies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Drugs Used in NHL Therapy
    • 4.3.2 Side Effects Associated with NHL Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Therapy
    • 5.1.1 Chemotherapy
    • 5.1.2 Radiation Therapy
    • 5.1.3 Targeted Therapy
    • 5.1.4 Other Types of Therapies
  • 5.2 By Cell Type
    • 5.2.1 B-cell Lymphomas
    • 5.2.2 T-cell Lymphoma
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca PLC
    • 6.1.2 Baxter International Inc.
    • 6.1.3 Bayer AG
    • 6.1.4 Bristol Myers Squibb Company
    • 6.1.5 Eli Lilly and Company
    • 6.1.6 F. Hoffmann La-Roche Ltd
    • 6.1.7 GlaxoSmithKline PLC
    • 6.1.8 Seattle Genetics
    • 6.1.9 Teva Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS